It is designed to improve the involvement of the immune system in GC compared to other anti-HER2 therapies by enhancing binding to the activating Fc receptor FcγRIIIA (CD16A) and reducing binding to the inhibitory Fc receptor FcγRIIB (CD32B) through a specific modification in the Fc domain. This evidence concerns the gene FCGR3A and gastric cancer.